

Selective outcome reporting in psychotherapy for depression



Clara Miguel
Eirini Karyotaki
Pim Cuijpers
Ioana A. Cristea

Evaluating interventions

Meta-analyses: gold-standard for examining effects

Potential sources of bias:

- Low quality of RCTs
- Researcher allegiance
- Publication bias, etc.

OVERESTIMATION OF TREATMENT EFFECTS


Selective outcome reporting (SOR)

Publication of **selected outcomes** within a study



Positive or **significant** outcomes have double the chance of being correctly reported

SOR in psychotherapy for depression



SOR in psychotherapy for depression

However:

- Previous studies examined SOR in a small and selected samples of trials
- Difficult to reliably estimate the prevalence of selective reporting
- Still unclear whether and by what extent it can influence the estimation of psychotherapy effects

Objectives

Estimate the **prevalence** of SOR across a complete cohort of trials of psychotherapy for depression

Examine the **influence** of SOR on psychotherapy effects



How did we examine SOR?



How did we examine SOR?

Trial publications



Meta-analytic database RCTs
psychotherapy for depression
After July 2005

Trial registrations



Protocols from public clinical
registries
Prospectively registered

How did we examine SOR?

Meta-analytic database (N= 353 RCTs)

- *Registered?*
 - *Publication*
 - *Searches in registries*
- *Prospectively registered?*
 - *Within 1 month enrollment start*

RESEARCH ARTICLE Open Access

Psychotherapy effectiveness for major depression: a randomized trial in a Finnish community

Hannu P. Saloheimo^{1*}, John Markowitz², Tuija H. Saloheimo¹, Jarmo J. Laitinen¹, Jari Sundell⁴, Matti O. Huttunen⁵, Timo A. Aro⁶, Tuitu N. Mikkonen³ and Heikki O. Katila⁵

Abstract

Background: The purpose of this study is to assess the relative effectiveness of Interpersonal Psychotherapy (IPT), Psychoeducative Group Therapy (PeGT), and treatment as usual (TAU) for patients with Major Depressive Disorder (MDD) in municipal psychiatric secondary care in one Finnish region.

Methods: All adult patients (N= 1515) with MDD symptoms referred to secondary care in 2004-2006 were screened. Eligible, consenting patients were assigned randomly to 10-week IPT (N= 46), PeGT (N= 42), or TAU (N= 46) treatment arms. Antidepressant pharmacotherapy among study participants was evaluated. The Hamilton Depression Rating scale (HAM-D) was the primary outcome measure. Assessment occurred at 1, 5, 3, 6, and 12 months. Actual amount of therapists' labor was also evaluated. All statistical analyses were

Conclusion: All three treatments notably benefited highly co-occurring anxiety disorders. At 3 months, 42 % in secondary care unit. After 12 months, these

Trial registration: ClinicalTrials.gov NCT02314767 (09.12.2014).

[Home](#) > [Search Results](#) > Study Record Detail

A Finnish Community Randomized Psychothera



The safety and scientific validity of this study is the responsibility of the study investigators. Listing a study does not mean it has been evaluated by the U.S. Government. Read our [disclaimer](#) for details.

ClinicalTrials.gov Identifier: NCT02314767

Recruitment Status ⓘ : Completed

First Posted ⓘ : December 11, 2014

Last Update Posted ⓘ : December 11, 2014

Sponsor:

Helsinki University Central Hospital

Information provided by (Responsible Party):

HSaloheimo, Helsinki University Central Hospital

Study Details

Tabular View

No Results Posted

Disclaimer

How to Read a Study Record

Study Description

Go to



Brief Summary:

Assessing selective outcome reporting



Trial publications

Primary outcome




Prospective Trial registrations

Assessing selective outcome reporting

≠ DISCREPANCIES

- Omission of registered primary outcome (non-reporting)
- Addition of new, not registered, primary outcome
- Downgrading of registered primary outcome to secondary
- Upgrading of secondary registered outcome to primary
- Assessment time point changes
- Analysis method changes



Statistical analyses


Counts and proportions

Standardized mean differences (SMD) based on reported primary outcome


Pooled using robust variance estimation (RVE)

Stata/SE 16.1


Results



Discrepancies



Selective outcome reporting



Discussion

- Evidence of SOR on psychotherapy research for depression
- Almost 1 in every 3 trials had changes in the primary outcome
- High risk of SOR was associated with inflated treatment effects (+ 0.27 SMD)
- Trials with non-reported outcome or addition of non-registered outcomes were the main drivers of inflation

Limitations

Availability bias (16% analyzed)

Imprecise registrations & changes in analysis method

Conclusion



Trial registration and other practices for increasing transparency



Considering SOR when examining treatment effects



Best evidence for decision-making

Thank you for your attention



Clara Miguel – clara.miguelsanz@vu.nl

Eirini Karyotaki

Pim Cuijpers

Ioana A. Cristea